Your browser doesn't support javascript.
loading
[Pressure Compatibility Test of Closed System Drug Transfer Devices for 71 Anticancer Drugs].
Ishimaru, Hiromasa; Tsuda, Yasumasa; Kage, Hidenori; Kawano, Tomoaki; Takayama, Shinji; Morimoto, Yoshihito; Goto, Kazumi; Watanabe, Kazuhiro.
Afiliação
  • Ishimaru H; Department of Pharmacy, St. Luke's International Hospital.
  • Tsuda Y; Education and Research Center for Clinical Pharmacy, Showa Pharmaceutical University.
  • Kage H; Department of Pharmacy, St. Luke's International Hospital.
  • Kawano T; Department of Pharmacy, St. Luke's International Hospital.
  • Takayama S; Department of Pharmacy, St. Luke's International Hospital.
  • Morimoto Y; Department of Pharmacy, St. Luke's International Hospital.
  • Goto K; Education and Research Center for Clinical Pharmacy, Showa Pharmaceutical University.
  • Watanabe K; Department of Pharmacy, St. Luke's International Hospital.
Yakugaku Zasshi ; 141(1): 143-150, 2021.
Article em Ja | MEDLINE | ID: mdl-33390441
Occupational exposure to anticancer drugs may increase the risk of cancer and the risk of miscarriage and stillbirth, and cause other adverse events such as hypersensitivity reactions, skin/mucous reactions, and digestive symptoms. Several studies have investigated the use of closed-system drug-transfer devices (CSTDs) to reduce the environmental pollution by hazardous drugs. However, few reports have verified whether CSTDs contain the hazardous drugs within the vials. The BD PhaSealTM System is a CSTD that is frequently used in Japan. However, the fit of each anti-cancer drug vial has not been investigated. We investigated the fit of 71 major anti-cancer drug vials and protectors released and frequently used in Japan by means of a pressure compatibility test that we developed. The pressure compatibility test involved attaching a three-way stopcock to a Luer lock syringe and attaching an injector in line with the syringe. The pressure tubing was connected to the other side of the three-way stopcock and connected to the pressure inlet of the pressure gauge. The pressure in the anti-cancer drug vial was raised to 100 kPa and connected/disconnected repeatedly. If the pressure fluctuation during the 10th connection was within 6%, it was defined as "no change", and the compatibility of the protector and the vial was evaluated. The median pressure reduction rates at the 10th connection ranged from -1.98% to -4.95%. All drugs surveyed had an error rate within 6%. The BD PhaSealTM Protector was shown to be compatible with the 71 anti-cancer drugs we surveyed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pressão / Seringas / Exposição Ocupacional / Composição de Medicamentos / Embalagem de Medicamentos / Poluição Ambiental / Desenho de Equipamento / Antineoplásicos Limite: Humans Idioma: Ja Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pressão / Seringas / Exposição Ocupacional / Composição de Medicamentos / Embalagem de Medicamentos / Poluição Ambiental / Desenho de Equipamento / Antineoplásicos Limite: Humans Idioma: Ja Ano de publicação: 2021 Tipo de documento: Article